Cargando…
Antigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomab
Acute lymphoblastic leukemia (ALL) arises from immature B and T lymphoblasts. An increasing array of cytogenetic and molecular markers have been identified in ALL, which allows for increasingly sophisticated prognostication, as well as identification of potential new targets for therapy. The treatme...
Autor principal: | Litzow, Mark R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918236/ https://www.ncbi.nlm.nih.gov/pubmed/27471701 http://dx.doi.org/10.2147/ITT.S37292 |
Ejemplares similares
-
Recent advances on blinatumomab for acute lymphoblastic leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019) -
Advancements in Therapy for Acute Lymphoblastic Leukemia: Blinatumomab
por: Hladnik,1, Lindsay, et al.
Publicado: (2016) -
Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
por: Le Jeune, Caroline, et al.
Publicado: (2016) -
Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
por: Franquiz, Miguel J, et al.
Publicado: (2020) -
Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia
por: Jain, Tania, et al.
Publicado: (2020)